Over the past decade, aqueous humor liquid biopsy has emerged as a transformative tool in ocular oncology, enabling minimally invasive molecular profiling of intraocular tumors from small-volume aqueous samples. Pioneered in retinoblastoma, this work demonstrated that cell-free DNA and ctDNA correlate with disease activity and prognosis, and that RB1 mutations can be reliably tracked across treatment. These findings established the clinical foundation for the LBSeq4Kids platform. Serial aqueous sampling has since proven valuable for guiding therapy and identifying patients at risk for metastatic progression without systemic biopsy. Now, this liquid biopsy framework is being extended to uveal melanoma, where modeled aqueous humor protein concentrations are opening a new avenue for biomarker discovery and non-invasive disease characterization.
MomentUM seminars aim to foster innovative ideas and collaborations in the field of uveal melanoma. No registration is required. Join in person at Institut Curie or online via the Teams link.
Speaker: Dr. Jesse Berry, Chief of Ophthalmology, Director of the Vision Center, and Director of the Ocular Oncology and Retinoblastoma Programs at Children's Hospital Los Angeles
Host: The Uveal Melanoma Medico-Scientific Program, Institut Curie
Contact: leanne.de-koning@curie.fr
Registration: Not required
Teams Link: https://teams.microsoft.com/meet/32850157888167?p=Jt3dNzOIAQWv4T4UbN